LINK . SPRINGER . COM {}

Matching Content Categories {📚}

• Education
• Health & Fitness
• Non-Profit & Charity

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,643,078 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

cancer, article, pubmed, google, scholar, olaparib, cas, astrazeneca, patients, research, ovarian, tablet, brca, study, dose, phase, funding, advanced, clinical, trial, oncol, advisory, oncology, institute, received, board, solid, polymerase, mutations, lancet, attendance, privacy, cookies, content, personal, formulation, inhibitor, drug, tumours, trials, access, nature, polyadpribose, breast, centre, university, publish, search, gourley, ledermann,

Topics {✒️}

/media/press-releases/article/20141218--lynparza-approved gov/drugs/informationondrugs/approveddrugs/ucm427598 recurrent high-grade serous month download article/chapter brcam breast/ovarian cancers triple-negative breast cancer early-phase clinical trials ovarian carcinoma cases /responsibility/code-policies-standards/ simplifying drug administration germ-line brca1/2 mutation population pharmacokinetic meta-analysis recurrent ovarian cancer full article pdf epithelial ovarian cancer ovarian carcinoma tablet dose escalation privacy choices/manage cookies olaparib maintenance therapy advanced breast cancer advanced solid tumours recommended monotherapy dose steady-state exposure phase iii trials parp inhibitor olaparib national research committee investigator-initiated trials clinical trial evaluated medical writing assistance natl cancer inst gynecological cancer intergroup individual participants included wales clinical school brca mutation carriers cancer research uk brca2-deficient tumours tablets ≥300 mg matched cancer therapy intermittent tablet administration scope submit manuscript reduce pill burden check access integrated genomic analyses gene expression profile claire routley phd attended advisory boards ema regulatory submission bristol-myers squibb advisory board attendance advisory board payment

Schema {🗺️}

WebPage:
      mainEntity:
         headline:An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
         description:Olaparib is poorly soluble, requiring advanced drug delivery technologies for adequate bioavailability. Sixteen capsules/day are required for the approved 400 mg twice-daily dose; a tablet formulation was developed to reduce pill burden. This clinical trial evaluated the optimal dose and administration schedule of the tablet formulation. Two stages of sequentially enrolled cohorts: stage 1, pharmacokinetic properties of tablet and capsule formulations were compared in patients with advanced solid tumours; stage 2, tablet dose escalation with expansion cohorts at doses/schedules of interest in patients with solid tumours and BRCAm breast/ovarian cancers. Olaparib 200 mg tablets displayed similar Cmax,ss, but lower AUCss and Cmin,ss than 400 mg capsules. Following multiple dosing, steady-state exposure with tablets ≥300 mg matched or exceeded that of 400 mg capsules. After dose escalation, while 400 mg twice daily was the tablet maximum tolerated dose based on haematological toxicity, 65 % of patients in the randomized expansion phase eventually required dose reduction to 300 mg. Intermittent tablet administration did not significantly improve tolerability. Tumour shrinkage was similar for 300 and 400 mg tablet and 400 mg capsule cohorts. The recommended monotherapy dose of olaparib tablet for Phase III trials was 300 mg twice daily, simplifying drug administration from 16 capsules to four tablets per day. NCT00777582 (ClinicalTrials.gov)
         datePublished:2016-05-12T00:00:00Z
         dateModified:2016-05-12T00:00:00Z
         pageStart:401
         pageEnd:415
         sameAs:https://doi.org/10.1007/s11523-016-0435-8
         keywords:
            Maximum Tolerate Dose
            Ovarian Cancer Patient
            Antitumour Activity
            Serous Ovarian Carcinoma
            Tablet Dose
            Oncology
            Biomedicine
            general
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0435-8/MediaObjects/11523_2016_435_Fig1_HTML.gif
         isPartOf:
            name:Targeted Oncology
            issn:
               1776-260X
               1776-2596
            volumeNumber:11
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:J. Mateo
               affiliation:
                     name:The Royal Marsden/The Institute of Cancer Research
                     address:
                        name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:V. Moreno
               affiliation:
                     name:The Royal Marsden/The Institute of Cancer Research
                     address:
                        name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. Gupta
               affiliation:
                     name:University of Oxford
                     address:
                        name:Department of Oncology, University of Oxford, Oxford, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S. B. Kaye
               affiliation:
                     name:The Royal Marsden/The Institute of Cancer Research
                     address:
                        name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:E. Dean
               affiliation:
                     name:The Christie NHS Foundation Trust/University of Manchester
                     address:
                        name:Clinical Trials Unit, The Christie NHS Foundation Trust/University of Manchester, Manchester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. R. Middleton
               affiliation:
                     name:University of Oxford
                     address:
                        name:Department of Oncology, University of Oxford, Oxford, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Friedlander
               affiliation:
                     name:University of New South Wales, Prince of Wales Hospital
                     address:
                        name:Prince of Wales Clinical School, University of New South Wales, Prince of Wales Hospital, Randwick, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:C. Gourley
               affiliation:
                     name:University of Edinburgh Cancer Research UK Centre, MRC IGMM
                     address:
                        name:University of Edinburgh Cancer Research UK Centre, MRC IGMM, Edinburgh, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R. Plummer
               affiliation:
                     name:Northern Centre for Cancer Care
                     address:
                        name:Northern Centre for Cancer Care, Newcastle-upon-Tyne, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:G. Rustin
               affiliation:
                     name:Mount Vernon Hospital
                     address:
                        name:Mount Vernon Hospital, Northwood, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:C. Sessa
               affiliation:
                     name:Oncology Institute of Southern Switzerland
                     address:
                        name:Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:K. Leunen
               affiliation:
                     name:University Hospitals Leuven
                     address:
                        name:Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J. Ledermann
               affiliation:
                     name:UCL Hospitals and UCL Cancer Institute
                     address:
                        name:UCL Hospitals and UCL Cancer Institute, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:H. Swaisland
               affiliation:
                     name:AstraZeneca
                     address:
                        name:AstraZeneca, Macclesfield, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. Fielding
               affiliation:
                     name:AstraZeneca
                     address:
                        name:AstraZeneca, Macclesfield, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:W. Bannister
               affiliation:
                     name:PHASTAR
                     address:
                        name:PHASTAR, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S. Nicum
               affiliation:
                     name:University of Oxford
                     address:
                        name:Department of Oncology, University of Oxford, Oxford, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:L. R. Molife
               affiliation:
                     name:The Royal Marsden/The Institute of Cancer Research
                     address:
                        name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
      description:Olaparib is poorly soluble, requiring advanced drug delivery technologies for adequate bioavailability. Sixteen capsules/day are required for the approved 400 mg twice-daily dose; a tablet formulation was developed to reduce pill burden. This clinical trial evaluated the optimal dose and administration schedule of the tablet formulation. Two stages of sequentially enrolled cohorts: stage 1, pharmacokinetic properties of tablet and capsule formulations were compared in patients with advanced solid tumours; stage 2, tablet dose escalation with expansion cohorts at doses/schedules of interest in patients with solid tumours and BRCAm breast/ovarian cancers. Olaparib 200 mg tablets displayed similar Cmax,ss, but lower AUCss and Cmin,ss than 400 mg capsules. Following multiple dosing, steady-state exposure with tablets ≥300 mg matched or exceeded that of 400 mg capsules. After dose escalation, while 400 mg twice daily was the tablet maximum tolerated dose based on haematological toxicity, 65 % of patients in the randomized expansion phase eventually required dose reduction to 300 mg. Intermittent tablet administration did not significantly improve tolerability. Tumour shrinkage was similar for 300 and 400 mg tablet and 400 mg capsule cohorts. The recommended monotherapy dose of olaparib tablet for Phase III trials was 300 mg twice daily, simplifying drug administration from 16 capsules to four tablets per day. NCT00777582 (ClinicalTrials.gov)
      datePublished:2016-05-12T00:00:00Z
      dateModified:2016-05-12T00:00:00Z
      pageStart:401
      pageEnd:415
      sameAs:https://doi.org/10.1007/s11523-016-0435-8
      keywords:
         Maximum Tolerate Dose
         Ovarian Cancer Patient
         Antitumour Activity
         Serous Ovarian Carcinoma
         Tablet Dose
         Oncology
         Biomedicine
         general
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0435-8/MediaObjects/11523_2016_435_Fig1_HTML.gif
      isPartOf:
         name:Targeted Oncology
         issn:
            1776-260X
            1776-2596
         volumeNumber:11
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:J. Mateo
            affiliation:
                  name:The Royal Marsden/The Institute of Cancer Research
                  address:
                     name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:V. Moreno
            affiliation:
                  name:The Royal Marsden/The Institute of Cancer Research
                  address:
                     name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. Gupta
            affiliation:
                  name:University of Oxford
                  address:
                     name:Department of Oncology, University of Oxford, Oxford, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S. B. Kaye
            affiliation:
                  name:The Royal Marsden/The Institute of Cancer Research
                  address:
                     name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:E. Dean
            affiliation:
                  name:The Christie NHS Foundation Trust/University of Manchester
                  address:
                     name:Clinical Trials Unit, The Christie NHS Foundation Trust/University of Manchester, Manchester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. R. Middleton
            affiliation:
                  name:University of Oxford
                  address:
                     name:Department of Oncology, University of Oxford, Oxford, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Friedlander
            affiliation:
                  name:University of New South Wales, Prince of Wales Hospital
                  address:
                     name:Prince of Wales Clinical School, University of New South Wales, Prince of Wales Hospital, Randwick, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:C. Gourley
            affiliation:
                  name:University of Edinburgh Cancer Research UK Centre, MRC IGMM
                  address:
                     name:University of Edinburgh Cancer Research UK Centre, MRC IGMM, Edinburgh, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. Plummer
            affiliation:
                  name:Northern Centre for Cancer Care
                  address:
                     name:Northern Centre for Cancer Care, Newcastle-upon-Tyne, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:G. Rustin
            affiliation:
                  name:Mount Vernon Hospital
                  address:
                     name:Mount Vernon Hospital, Northwood, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:C. Sessa
            affiliation:
                  name:Oncology Institute of Southern Switzerland
                  address:
                     name:Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:K. Leunen
            affiliation:
                  name:University Hospitals Leuven
                  address:
                     name:Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J. Ledermann
            affiliation:
                  name:UCL Hospitals and UCL Cancer Institute
                  address:
                     name:UCL Hospitals and UCL Cancer Institute, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:H. Swaisland
            affiliation:
                  name:AstraZeneca
                  address:
                     name:AstraZeneca, Macclesfield, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. Fielding
            affiliation:
                  name:AstraZeneca
                  address:
                     name:AstraZeneca, Macclesfield, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:W. Bannister
            affiliation:
                  name:PHASTAR
                  address:
                     name:PHASTAR, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S. Nicum
            affiliation:
                  name:University of Oxford
                  address:
                     name:Department of Oncology, University of Oxford, Oxford, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:L. R. Molife
            affiliation:
                  name:The Royal Marsden/The Institute of Cancer Research
                  address:
                     name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Targeted Oncology
      issn:
         1776-260X
         1776-2596
      volumeNumber:11
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The Royal Marsden/The Institute of Cancer Research
      address:
         name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
         type:PostalAddress
      name:The Royal Marsden/The Institute of Cancer Research
      address:
         name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
         type:PostalAddress
      name:University of Oxford
      address:
         name:Department of Oncology, University of Oxford, Oxford, UK
         type:PostalAddress
      name:The Royal Marsden/The Institute of Cancer Research
      address:
         name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
         type:PostalAddress
      name:The Christie NHS Foundation Trust/University of Manchester
      address:
         name:Clinical Trials Unit, The Christie NHS Foundation Trust/University of Manchester, Manchester, UK
         type:PostalAddress
      name:University of Oxford
      address:
         name:Department of Oncology, University of Oxford, Oxford, UK
         type:PostalAddress
      name:University of New South Wales, Prince of Wales Hospital
      address:
         name:Prince of Wales Clinical School, University of New South Wales, Prince of Wales Hospital, Randwick, Australia
         type:PostalAddress
      name:University of Edinburgh Cancer Research UK Centre, MRC IGMM
      address:
         name:University of Edinburgh Cancer Research UK Centre, MRC IGMM, Edinburgh, UK
         type:PostalAddress
      name:Northern Centre for Cancer Care
      address:
         name:Northern Centre for Cancer Care, Newcastle-upon-Tyne, UK
         type:PostalAddress
      name:Mount Vernon Hospital
      address:
         name:Mount Vernon Hospital, Northwood, UK
         type:PostalAddress
      name:Oncology Institute of Southern Switzerland
      address:
         name:Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
         type:PostalAddress
      name:University Hospitals Leuven
      address:
         name:Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium
         type:PostalAddress
      name:UCL Hospitals and UCL Cancer Institute
      address:
         name:UCL Hospitals and UCL Cancer Institute, London, UK
         type:PostalAddress
      name:AstraZeneca
      address:
         name:AstraZeneca, Macclesfield, UK
         type:PostalAddress
      name:AstraZeneca
      address:
         name:AstraZeneca, Macclesfield, UK
         type:PostalAddress
      name:PHASTAR
      address:
         name:PHASTAR, London, UK
         type:PostalAddress
      name:University of Oxford
      address:
         name:Department of Oncology, University of Oxford, Oxford, UK
         type:PostalAddress
      name:The Royal Marsden/The Institute of Cancer Research
      address:
         name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:J. Mateo
      affiliation:
            name:The Royal Marsden/The Institute of Cancer Research
            address:
               name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
               type:PostalAddress
            type:Organization
      name:V. Moreno
      affiliation:
            name:The Royal Marsden/The Institute of Cancer Research
            address:
               name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
               type:PostalAddress
            type:Organization
      name:A. Gupta
      affiliation:
            name:University of Oxford
            address:
               name:Department of Oncology, University of Oxford, Oxford, UK
               type:PostalAddress
            type:Organization
      name:S. B. Kaye
      affiliation:
            name:The Royal Marsden/The Institute of Cancer Research
            address:
               name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
               type:PostalAddress
            type:Organization
      name:E. Dean
      affiliation:
            name:The Christie NHS Foundation Trust/University of Manchester
            address:
               name:Clinical Trials Unit, The Christie NHS Foundation Trust/University of Manchester, Manchester, UK
               type:PostalAddress
            type:Organization
      name:M. R. Middleton
      affiliation:
            name:University of Oxford
            address:
               name:Department of Oncology, University of Oxford, Oxford, UK
               type:PostalAddress
            type:Organization
      name:M. Friedlander
      affiliation:
            name:University of New South Wales, Prince of Wales Hospital
            address:
               name:Prince of Wales Clinical School, University of New South Wales, Prince of Wales Hospital, Randwick, Australia
               type:PostalAddress
            type:Organization
      name:C. Gourley
      affiliation:
            name:University of Edinburgh Cancer Research UK Centre, MRC IGMM
            address:
               name:University of Edinburgh Cancer Research UK Centre, MRC IGMM, Edinburgh, UK
               type:PostalAddress
            type:Organization
      name:R. Plummer
      affiliation:
            name:Northern Centre for Cancer Care
            address:
               name:Northern Centre for Cancer Care, Newcastle-upon-Tyne, UK
               type:PostalAddress
            type:Organization
      name:G. Rustin
      affiliation:
            name:Mount Vernon Hospital
            address:
               name:Mount Vernon Hospital, Northwood, UK
               type:PostalAddress
            type:Organization
      name:C. Sessa
      affiliation:
            name:Oncology Institute of Southern Switzerland
            address:
               name:Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
               type:PostalAddress
            type:Organization
      name:K. Leunen
      affiliation:
            name:University Hospitals Leuven
            address:
               name:Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium
               type:PostalAddress
            type:Organization
      name:J. Ledermann
      affiliation:
            name:UCL Hospitals and UCL Cancer Institute
            address:
               name:UCL Hospitals and UCL Cancer Institute, London, UK
               type:PostalAddress
            type:Organization
      name:H. Swaisland
      affiliation:
            name:AstraZeneca
            address:
               name:AstraZeneca, Macclesfield, UK
               type:PostalAddress
            type:Organization
      name:A. Fielding
      affiliation:
            name:AstraZeneca
            address:
               name:AstraZeneca, Macclesfield, UK
               type:PostalAddress
            type:Organization
      name:W. Bannister
      affiliation:
            name:PHASTAR
            address:
               name:PHASTAR, London, UK
               type:PostalAddress
            type:Organization
      name:S. Nicum
      affiliation:
            name:University of Oxford
            address:
               name:Department of Oncology, University of Oxford, Oxford, UK
               type:PostalAddress
            type:Organization
      name:L. R. Molife
      affiliation:
            name:The Royal Marsden/The Institute of Cancer Research
            address:
               name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
      name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
      name:Department of Oncology, University of Oxford, Oxford, UK
      name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
      name:Clinical Trials Unit, The Christie NHS Foundation Trust/University of Manchester, Manchester, UK
      name:Department of Oncology, University of Oxford, Oxford, UK
      name:Prince of Wales Clinical School, University of New South Wales, Prince of Wales Hospital, Randwick, Australia
      name:University of Edinburgh Cancer Research UK Centre, MRC IGMM, Edinburgh, UK
      name:Northern Centre for Cancer Care, Newcastle-upon-Tyne, UK
      name:Mount Vernon Hospital, Northwood, UK
      name:Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
      name:Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium
      name:UCL Hospitals and UCL Cancer Institute, London, UK
      name:AstraZeneca, Macclesfield, UK
      name:AstraZeneca, Macclesfield, UK
      name:PHASTAR, London, UK
      name:Department of Oncology, University of Oxford, Oxford, UK
      name:Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Sutton, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(136)

• What is the monthly revenue of https://www.springernature.com/gp/authors?
• Learn about the earnings of https://link.springernature.com/home/
• How much does https://order.springer.com/public/cart generate monthly?
• How much income does https://www.editorialmanager.com/targ have?
• What is the monthly revenue of https://www.springernature.com/gp/librarians/licensing/agc/journals?
• Revenue of https://doi.org/10.1038%2Fnature03445
• Check the income stats for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15829967
• http://scholar.google.com/scholar_lookup?&title=Targeting%20the%20DNA%20repair%20defect%20in%20BRCA%20mutant%20cells%20as%20a%20therapeutic%20strategy&journal=Nature&doi=10.1038%2Fnature03445&volume=434&pages=917-921&publication_year=2005&author=Farmer%2CH&author=McCabe%2CN&author=Lord%2CCJ's revenue stream
• How much does https://doi.org/10.1038%2Fnature03443 bring in each month?
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15829966's financial summary
• http://scholar.google.com/scholar_lookup?&title=Specific%20killing%20of%20BRCA2-deficient%20tumours%20with%20inhibitors%20of%20poly%28ADP-ribose%29%20polymerase&journal=Nature&doi=10.1038%2Fnature03443&volume=434&pages=913-917&publication_year=2005&author=Bryant%2CHE&author=Schultz%2CN&author=Thomas%2CHD income
• How much does https://doi.org/10.1002%2Fcncr.21536 generate monthly?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16284991 make?
• Monthly income for http://scholar.google.com/scholar_lookup?&title=BRCA1%20and%20BRCA2%20mutations%20account%20for%20a%20large%20proportion%20of%20ovarian%20carcinoma%20cases&journal=Cancer&doi=10.1002%2Fcncr.21536&volume=104&pages=2807-2816&publication_year=2005&author=Pal%2CT&author=Permuth-Wey%2CJ&author=Betts%2CJA
• How much income does https://doi.org/10.1038%2Fnature10166 have?
• Monthly income for http://scholar.google.com/scholar_lookup?&title=Integrated%20genomic%20analyses%20of%20ovarian%20carcinoma&journal=Nature&doi=10.1038%2Fnature10166&volume=474&pages=609-615&publication_year=2011
• What's the monthly money flow for https://doi.org/10.1158%2F1078-0432.CCR-10-2560?
• Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21233401's earnings
• What's http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048924's gross income?
• http://scholar.google.com/scholar_lookup?&title=Incidence%20and%20outcome%20of%20BRCA%20mutations%20in%20unselected%20patients%20with%20triple%20receptor-negative%20breast%20cancer&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-10-2560&volume=17&pages=1082-1089&publication_year=2011&author=Gonzalez-Angulo%2CAM&author=Timms%2CKM&author=Liu%2CS's financial summary
• How profitable is https://doi.org/10.1002%2Fcncr.26576?
• Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22614657
• What's http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20BRCA%20mutations%20in%20an%20unselected%20population%20of%20triple-negative%20breast%20cancer&journal=Cancer&doi=10.1002%2Fcncr.26576&volume=118&pages=2787-2795&publication_year=2012&author=Hartman%2CAR&author=Kaldate%2CRR&author=Sailer%2CLM's gross income?
• https://doi.org/10.1056%2FNEJMoa0900212's total income per month
• What's the revenue for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19553641?
• What is the earnings of http://scholar.google.com/scholar_lookup?&title=Inhibition%20of%20poly%28ADP-ribose%29%20polymerase%20in%20tumors%20from%20BRCA%20mutation%20carriers&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa0900212&volume=361&pages=123-134&publication_year=2009&author=Fong%2CPC&author=Boss%2CDS&author=Yap%2CTA?
• What's the income generated by https://doi.org/10.1016%2FS0140-6736%2810%2960893-8 each month?
• What's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20609468?
• What's the revenue for http://scholar.google.com/scholar_lookup?&title=Oral%20poly%28ADP-ribose%29%20polymerase%20inhibitor%20olaparib%20in%20patients%20with%20BRCA1%20or%20BRCA2%20mutations%20and%20recurrent%20ovarian%20cancer%3A%20a%20proof-of-concept%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2810%2960893-8&volume=376&pages=245-251&publication_year=2010&author=Audeh%2CMW&author=Carmichael%2CJ&author=Penson%2CRT?
• Get to know https://doi.org/10.1016%2FS0140-6736%2810%2960892-6's earnings
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20609467 make?
• Revenue of http://scholar.google.com/scholar_lookup?&title=Oral%20poly%28ADP-ribose%29%20polymerase%20inhibitor%20olaparib%20in%20patients%20with%20BRCA1%20or%20BRCA2%20mutations%20and%20advanced%20breast%20cancer%3A%20a%20proof-of-concept%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2810%2960892-6&volume=376&pages=235-244&publication_year=2010&author=Tutt%2CA&author=Robson%2CM&author=Garber%2CJE
• How much does https://doi.org/10.1200%2FJCO.2011.36.9215 generate monthly?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22203755 pull in monthly?
• What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Phase%20II%2C%20open-label%2C%20randomized%2C%20multicenter%20study%20comparing%20the%20efficacy%20and%20safety%20of%20olaparib%2C%20a%20poly%20%28ADP-ribose%29%20polymerase%20inhibitor%2C%20and%20pegylated%20liposomal%20doxorubicin%20in%20patients%20with%20BRCA1%20or%20BRCA2%20mutations%20and%20recurrent%20ovarian%20cancer&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2011.36.9215&volume=30&pages=372-379&publication_year=2012&author=Kaye%2CSB&author=Lubinski%2CJ&author=Matulonis%2CU?
• How much does https://doi.org/10.1200%2FJCO.2014.56.2728 gross monthly?
• What's the profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25366685?
• What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Olaparib%20monotherapy%20in%20patients%20with%20advanced%20cancer%20and%20a%20germ-line%20BRCA1%2F2%20mutation&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2014.56.2728&volume=33&pages=244-250&publication_year=2015&author=Kaufman%2CB&author=Shapira-Frommer%2CR&author=Schmutzler%2CRK?
• Revenue of https://doi.org/10.1016%2FS1470-2045%2811%2970214-5
• What's the financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21862407?
• How much does http://scholar.google.com/scholar_lookup?&title=Olaparib%20in%20patients%20with%20recurrent%20high-grade%20serous%20or%20poorly%20differentiated%20ovarian%20carcinoma%20or%20triple-negative%20breast%20cancer%3A%20a%20phase%202%2C%20multicentre%2C%20open-label%2C%20non-randomised%20study&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2811%2970214-5&volume=12&pages=852-861&publication_year=2011&author=Gelmon%2CKA&author=Tischkowitz%2CM&author=Mackay%2CH net monthly?
• How much money does https://doi.org/10.1200%2FJCO.2009.27.5719 make?
• Discover the revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20547991
• How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917311 rake in every month?
• What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=Gene%20expression%20profile%20of%20BRCAness%20that%20correlates%20with%20responsiveness%20to%20chemotherapy%20and%20with%20outcome%20in%20patients%20with%20epithelial%20ovarian%20cancer&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2009.27.5719&volume=28&pages=3555-3561&publication_year=2010&author=Konstantinopoulos%2CPA&author=Spentzos%2CD&author=Karlan%2CBY?
• What's the monthly income of https://doi.org/10.1038%2Fonc.2013.352?
• Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24037533
• How much does http://scholar.google.com/scholar_lookup?&title=Predictive%20biomarkers%20for%20cancer%20therapy%20with%20PARP%20inhibitors&journal=Oncogene&doi=10.1038%2Fonc.2013.352&volume=33&pages=3894-3907&publication_year=2014&author=Michels%2CJ&author=Vitale%2CI&author=Saparbaev%2CM bring in each month?
• What's the total monthly financial gain of https://doi.org/10.1158%2F0008-5472.CAN-06-0140?
• Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16912188
• Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Deficiency%20in%20the%20repair%20of%20DNA%20damage%20by%20homologous%20recombination%20and%20sensitivity%20to%20poly%28ADP-ribose%29%20polymerase%20inhibition&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-06-0140&volume=66&pages=8109-8115&publication_year=2006&author=McCabe%2CN&author=Turner%2CNC&author=Lord%2CCJ
• How much does https://doi.org/10.1056%2FNEJMoa1105535 rake in every month?
• Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22452356's earnings
• How much does http://scholar.google.com/scholar_lookup?&title=Olaparib%20maintenance%20therapy%20in%20platinum-sensitive%20relapsed%20ovarian%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1105535&volume=366&pages=1382-1392&publication_year=2012&author=Ledermann%2CJ&author=Harter%2CP&author=Gourley%2CC pull in monthly?
• How much does https://doi.org/10.1016%2FS1470-2045%2814%2970228-1 earn?
• Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24882434
• http://scholar.google.com/scholar_lookup?&title=Olaparib%20maintenance%20therapy%20in%20patients%20with%20platinum-sensitive%20relapsed%20serous%20ovarian%20cancer%3A%20a%20preplanned%20retrospective%20analysis%20of%20outcomes%20by%20BRCA%20status%20in%20a%20randomised%20phase%202%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2814%2970228-1&volume=15&pages=852-861&publication_year=2014&author=Ledermann%2CJ&author=Harter%2CP&author=Gourley%2CC income
• How much profit does http://www.astrazeneca.com/Media/Press-releases/Article/20141218--lynparza-approved-in-the-european-union generate?
• http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm427598.htm's financial summary
• See how much http://www.astrazeneca.com/Responsibility/Code-policies-standards/Our-global-policies makes per month
• https://doi.org/10.1093%2Fjnci%2F92.3.205's total income per month
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10655437 generate monthly?
• Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=New%20guidelines%20to%20evaluate%20the%20response%20to%20treatment%20in%20solid%20tumors.%20European%20Organization%20for%20Research%20and%20Treatment%20of%20Cancer%2C%20National%20Cancer%20Institute%20of%20the%20United%20States%2C%20National%20Cancer%20Institute%20of%20Canada&journal=J%20Natl%20Cancer%20Inst&doi=10.1093%2Fjnci%2F92.3.205&volume=92&pages=205-216&publication_year=2000&author=Therasse%2CP&author=Arbuck%2CSG&author=Eisenhauer%2CEA
• How much does https://doi.org/10.1097%2FIGC.0b013e3182070f17 bring in each month?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21270624 gross monthly?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Definitions%20for%20response%20and%20progression%20in%20ovarian%20cancer%20clinical%20trials%20incorporating%20RECIST%201.1%20and%20CA%20125%20agreed%20by%20the%20Gynecological%20Cancer%20Intergroup%20%28GCIG%29&journal=Int%20J%20Gynecol%20Cancer&doi=10.1097%2FIGC.0b013e3182070f17&volume=21&pages=419-423&publication_year=2011&author=Rustin%2CGJ&author=Vergote%2CI&author=Eisenhauer%2CE generate?
• Financial intake of https://doi.org/10.1016%2FS0140-6736%2809%2961338-6
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19793610's financial summary
• Explore the financials of http://scholar.google.com/scholar_lookup?&title=Ovarian%20cancer&journal=Lancet&doi=10.1016%2FS0140-6736%2809%2961338-6&volume=374&pages=1371-1382&publication_year=2009&author=Hennessy%2CBT&author=Coleman%2CRL&author=Markman%2CM
• How much money does https://doi.org/10.1093%2Fannonc%2Fmdu187 make?
• Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24827126
• How much income is http://scholar.google.com/scholar_lookup?&title=Phase%20I%20trial%20of%20olaparib%20in%20combination%20with%20cisplatin%20for%20the%20treatment%20of%20patients%20with%20advanced%20breast%2C%20ovarian%20and%20other%20solid%20tumors&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmdu187&volume=25&pages=1656-1663&publication_year=2014&author=Balmana%2CJ&author=Tung%2CNM&author=Isakoff%2CSJ earning monthly?
• How much does https://doi.org/10.1038%2Fbjc.2014.345 bring in each month?
• Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25025963
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134498's financial summary
• What's the revenue for http://scholar.google.com/scholar_lookup?&title=Phase%20I%20study%20of%20olaparib%20in%20combination%20with%20liposomal%20doxorubicin%20in%20patients%20with%20advanced%20solid%20tumours&journal=Br%20J%20Cancer&doi=10.1038%2Fbjc.2014.345&volume=111&pages=651-659&publication_year=2014&author=Conte%2CG&author=Sessa%2CC&author=Moos%2CR?
• How much does https://doi.org/10.1016%2FS1470-2045%2814%2971135-0 generate monthly?
• What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25481791?
• What are the total earnings of http://scholar.google.com/scholar_lookup?&title=Olaparib%20combined%20with%20chemotherapy%20for%20recurrent%20platinum-sensitive%20ovarian%20cancer%3A%20a%20randomised%20phase%202%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2814%2971135-0&volume=16&pages=87-97&publication_year=2015&author=Oza%2CAM&author=Cibula%2CD&author=Benzaquen%2CAO?
• How much profit does https://citation-needed.springer.com/v2/references/10.1007/s11523-016-0435-8?format=refman&flavour=references make?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=J.%20Mateo pull in monthly?
• What's the monthly money flow for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22J.%20Mateo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• What's the profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=V.%20Moreno?
• How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22V.%20Moreno%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=A.%20Gupta pull in?
• What's the total monthly financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22A.%20Gupta%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=S.%20B.%20Kaye
• What is the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22S.%20B.%20Kaye%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=E.%20Dean
• What's the financial outcome of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22E.%20Dean%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Income figures for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=M.%20R.%20Middleton
• Get to know what's the income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22M.%20R.%20Middleton%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=M.%20Friedlander bring in?
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22M.%20Friedlander%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in?
• What's the income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=C.%20Gourley?
• Revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22C.%20Gourley%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=R.%20Plummer's total income per month
• Learn how profitable https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22R.%20Plummer%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en is on a monthly basis
• What's the revenue for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=G.%20Rustin?
• Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22G.%20Rustin%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• Earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=C.%20Sessa
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22C.%20Sessa%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate monthly?
• Revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=K.%20Leunen
• What's the financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22K.%20Leunen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=J.%20Ledermann
• How much profit does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22J.%20Ledermann%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=H.%20Swaisland net monthly?
• Get to know https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22H.%20Swaisland%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's earnings
• How much profit does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=A.%20Fielding generate?
• What's the financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22A.%20Fielding%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=W.%20Bannister
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22W.%20Bannister%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=S.%20Nicum rake in every month?
• How much profit does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22S.%20Nicum%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• How much profit does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=L.%20R.%20Molife make?
• What's the monthly income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22L.%20R.%20Molife%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• What's the monthly income of https://static-content.springer.com/esm/art%3A10.1007%2Fs11523-016-0435-8/MediaObjects/11523_2016_435_MOESM1_ESM.docx?
• How much profit is https://s100.copyright.com/AppDispatchServlet?title=An%20Adaptive%20Study%20to%20Determine%20the%20Optimal%20Dose%20of%20the%20Tablet%20Formulation%20of%20the%20PARP%20Inhibitor%20Olaparib&author=J.%20Mateo%20et%20al&contentID=10.1007%2Fs11523-016-0435-8©right=Springer%20International%20Publishing%20Switzerland&publication=1776-2596&publicationDate=2016-05-12&publisherName=SpringerNature&orderBeanReset=true making per month?
• What are the earnings of https://crossmark.crossref.org/dialog/?doi=10.1007/s11523-016-0435-8?
• How much does https://citation-needed.springer.com/v2/references/10.1007/s11523-016-0435-8?format=refman&flavour=citation make?
• See how much https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral makes per month
• See how much https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research makes per month
• How much does https://www.springernature.com/gp/products pull in?
• Find out how much https://www.springernature.com/gp/librarians earns monthly
• What's the total monthly financial gain of https://www.springernature.com/gp/societies?
• Learn how profitable https://www.springernature.com/gp/partners is on a monthly basis
• How much does https://www.springer.com/ make?
• How much does https://www.nature.com/ gross monthly?
• What's the financial intake of https://www.biomedcentral.com/?
• How much money does https://www.palgrave.com/ generate?
• Profit of https://www.apress.com/
• How much profit is https://www.springernature.com/gp/legal/ccpa making per month?
• How much revenue does https://www.springernature.com/gp/info/accessibility bring in?
• What's the financial gain of https://support.springernature.com/en/support/home?
• Check the income stats for https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations
• Income figures for https://www.springernature.com/

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Clipboard.js
• Prism.js

CDN Services {📦}

• Crossref